Byondis is an independent, privately held, clinical stage biopharmaceutical company creating innovative precision medicines targeting intractable cancers and autoimmune diseases. Using its proprietary molecular concepts and technologies, Byondis generates next generation antibody-drug conjugates (ADCs). Its broad development portfolio includes the anti-HER2 ADC [vic-]trastuzumab duocarmazine (SYD985), whose pivotal Phase III TULIP® study reported positive topline results. Based in Nijmegen, the Netherlands, Byondis collaborates with leading biotechnology, pharmaceutical and academic research organizations.